Nature Medicine最新文献_第9页

Health impacts of exposure to synthetic chemicals in food 接触食品中合成化学品对健康的影响

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-05-16 DOI: 10.1038/s41591-025-03697-5

Jane Muncke, Mathilde Touvier, Leonardo Trasande, Martin Scheringer

引用次数: 0

Measles to become endemic in the USA if vaccination rates continue to fall 如果疫苗接种率继续下降，麻疹将成为美国的地方病

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-05-14 DOI: 10.1038/d41591-025-00031-x

引用次数: 0

Parallel worlds in pharma and academia 制药和学术界的平行世界

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-05-13 DOI: 10.1038/s41591-025-03710-x

Hans Clevers

引用次数: 0

The innate power of natural killer cells in cancer therapy 自然杀伤细胞在癌症治疗中的先天力量

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-05-12 DOI: 10.1038/s41591-025-03712-9

Ebba Sohlberg, Karl-Johan Malmberg

引用次数: 0

Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial ubrogeant治疗偏头痛前驱症状：来自随机3期PRODROME试验的探索性分析

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-05-12 DOI: 10.1038/s41591-025-03679-7

Peter J. Goadsby, Jessica Ailani, David W. Dodick, Amaal J. Starling, Chengcheng Liu, Yingyi Liu, Sung Yun Yu, Jonathan H. Smith, Elimor Brand-Schieber, Joel M. Trugman

{"title":"Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial","authors":"Peter J. Goadsby, Jessica Ailani, David W. Dodick, Amaal J. Starling, Chengcheng Liu, Yingyi Liu, Sung Yun Yu, Jonathan H. Smith, Elimor Brand-Schieber, Joel M. Trugman","doi":"10.1038/s41591-025-03679-7","DOIUrl":"https://doi.org/10.1038/s41591-025-03679-7","url":null,"abstract":"PRODROME was a phase 3, placebo-controlled, double-blind crossover trial evaluating whether ubrogepant 100 mg, a calcitonin gene-related peptide receptor antagonist, dosed during the premonitory (prodromal) phase of migraine, prevented development of headache and resolved prodromal symptoms. Qualifying prodromal events were defined as attacks with symptoms in which the participant was confident headache would follow within 1–6 h. Of 1,087 screened participants, 477 formed the efficacy analysis population. Outcomes were collected across 48 h showing, for example, at 2 h post-dose, absence of photophobia in 19.5% and 12.5% of ubrogepant- and placebo-treated events, respectively (odds ratio (OR) = 1.72 (95% confidence interval (CI) = 1.13–2.61)); at 3 h post-dose, absence of fatigue occurred in 27.3% and 16.8% (OR = 1.85 (95% CI = 1.17–2.92)) and absence of neck pain in 28.9% and 15.9% (OR = 2.04 (95% CI = 1.25–3.32)) of events; at 4 h post-dose, absence of phonophobia in 50.7% and 35.8% (OR = 1.97 (95% CI = 1.38–2.80)) of events; and at 24 h post-dose, absence of dizziness in 88.5% and 82.3% (OR = 1.82 (95% CI = 1.00–3.30)) of events. At 1 h and 6 h post-dose, respectively, absence of difficulty concentrating occurred in 8.7% and 2.1% (OR = 4.26 (95% CI = 1.17–15.54)) and absence of difficulty thinking occurred in 56.9% and 41.8% (OR = 2.05 (95% CI = 1.14–3.71)) of events. Treatment with ubrogepant during the prodromal phase may ameliorate common prodromal symptoms, with improvements possibly as early as 1 h post-dose.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"13 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143940542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence improves breast cancer detection in mammography screening 人工智能提高乳房x光检查中的乳腺癌检测

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-05-09 DOI: 10.1038/s41591-025-03714-7

引用次数: 0

Three decades of global dietary iron deficiency trends and disparities across populations 三十年来全球膳食铁缺乏趋势和人群差异

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-05-09 DOI: 10.1038/s41591-025-03696-6

引用次数: 0

RANO criteria for response assessment of brain metastases based on amino acid PET imaging 基于氨基酸PET成像的脑转移反应评估的RANO标准

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-05-08 DOI: 10.1038/s41591-025-03633-7

Nathalie L. Albert, Norbert Galldiks, Benjamin M. Ellingson, Martin J. van den Bent, Susan M. Chang, Francesco Cicone, Eng-Siew Koh, Ian Law, Emilie Le Rhun, Maximilian J. Mair, Jan-Michael Werner, Anna S. Berghoff, Julia Furtner, Giuseppe Minniti, Andrew M. Scott, Susan C. Short, Jana Ivanidze, Derek R. Johnson, Bogdana Suchorska, Nelleke Tolboom, Joerg-Christian Tonn, Antoine Verger, Eva Galanis, Priscilla K. Brastianos, Patrick Y. Wen, Michael Weller, Nancy U. Lin, Matthias Preusser

{"title":"RANO criteria for response assessment of brain metastases based on amino acid PET imaging","authors":"Nathalie L. Albert, Norbert Galldiks, Benjamin M. Ellingson, Martin J. van den Bent, Susan M. Chang, Francesco Cicone, Eng-Siew Koh, Ian Law, Emilie Le Rhun, Maximilian J. Mair, Jan-Michael Werner, Anna S. Berghoff, Julia Furtner, Giuseppe Minniti, Andrew M. Scott, Susan C. Short, Jana Ivanidze, Derek R. Johnson, Bogdana Suchorska, Nelleke Tolboom, Joerg-Christian Tonn, Antoine Verger, Eva Galanis, Priscilla K. Brastianos, Patrick Y. Wen, Michael Weller, Nancy U. Lin, Matthias Preusser","doi":"10.1038/s41591-025-03633-7","DOIUrl":"https://doi.org/10.1038/s41591-025-03633-7","url":null,"abstract":"Novel diagnostic and therapeutic opportunities are needed to improve medical care and outcome of patients with brain metastases, a frequent and severe complication of several cancer types. Currently, magnetic resonance imaging (MRI) is the primary method used for detection, treatment planning and disease monitoring in patients with brain metastases, but this method has limitations. These limitations mean that MRI can inform on lesion size but cannot directly measure the activity or viability of tumor tissue. Positron emission tomography (PET) imaging, however, can visualize metabolically active tumor cells and is therefore increasingly incorporated into cancer care to assess tumor burden and response to treatment. Here, we define the PET Response Assessment in Neuro-Oncology (RANO) for brain metastasis (BM) 1.0 criteria for metabolic response assessment of brain metastases using amino acid PET. By introducing an innovative endpoint for next-generation clinical trials, the PET RANO BM 1.0 criteria aim to facilitate development of novel therapies for patients with brain metastases.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"104 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The trials that could transform treatment for serious liver disease 这些试验可能会改变严重肝病的治疗方法

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-05-07 DOI: 10.1038/d41591-025-00030-y

引用次数: 0

Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver events 多器官MRI的心脏和肝脏损害与主要不良心血管和肝脏事件的风险

IF 82.9 1区医学

Nature Medicine Pub Date : 2025-05-07 DOI: 10.1038/s41591-025-03654-2

Edward Jackson, Andrea Dennis, Naim Alkhouri, Niharika Samala, Raj Vuppalanchi, Arun J. Sanyal, Mark Muthiah, Rajarshi Banerjee, Amitava Banerjee

{"title":"Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver events","authors":"Edward Jackson, Andrea Dennis, Naim Alkhouri, Niharika Samala, Raj Vuppalanchi, Arun J. Sanyal, Mark Muthiah, Rajarshi Banerjee, Amitava Banerjee","doi":"10.1038/s41591-025-03654-2","DOIUrl":"https://doi.org/10.1038/s41591-025-03654-2","url":null,"abstract":"Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease are common conditions associated with high mortality and morbidity, yet opportunities for integrated prevention are underinvestigated. We explored the association between impairment in the liver (defined by increased iron-corrected T1 (cT1) time) and/or heart (reduced left ventricular ejection fraction ≤ 50) and risk of experiencing cardiovascular- or liver-related events or all-cause mortality among 28,841 UK Biobank participants who underwent magnetic resonance imaging. Using Cox proportional hazard models, adjusted for age, sex, body mass index, type 2 diabetes and dyslipidaemia, we observed that cardiac impairment was associated with increased incidence of cardiovascular events (hazard ratio (HR) 2.3 (1.9–2.7)) and hospitalization (HR 2.1 (1.8–2.4)). Liver impairment was associated with incident cardiovascular hospitalization (cT1 ≥ 800 ms, HR 1.3 (1.1–1.5)), liver events (cT1 ≥ 875 ms, HR 9.2 (3.2–26) and hospitalization (cT1 ≥ 875 ms, HR 5.5 (3.2–9.3). Associations between cT1 and liver events were maintained in participants with metabolic dysfunction-associated steatotic liver disease (N = 6,223). Reduced left ventricular ejection fraction (≤50) combined with elevated cT1 (≥800 ms) were associated with earlier cardiovascular events (time to event 0.8 versus 2.4 years; P < 0.05). Cardiac and liver impairment are independently, or in combination, associated with cardiovascular or liver events, suggesting a dual role for magnetic resonance imaging in integrated prevention pathways.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"62 1","pages":""},"PeriodicalIF":82.9,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0